This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): Vitragan, hyaluronidase ovine
Description: Vitrase is a sheep derived (ovine) form of hyaluronidase, a group of naturally occurring enzymes that break down hyaluronic acid. Hyaluronic acid is a mucopolysaccharide (a type of carbohydrate) that forms the ground substance between cells in subcutaneous tissue.
Deal Structure: In September 2004, Ista entered into an agreement with Allergan replacing its previous Vitrase collaboration, and reacquired all rights to market and sell Vitrase for all uses in the United States and other specified markets. Under the new agreement, Ista agreed to pay Allergan approximately $10.0 million (paid in full in January 2005). Ista has also agreed to make royalty payments to Allergan on its U.S. sales of Vitrase for use in the posterior region of the eye (no royalties are do for use as a spreading agent). Allergan has an option to commercialize Vitrase in Europe subsequent to European Union product approval. If Allergan does not exercise its option, then such European rights will revert to Ista, and Allergan will be paid a royalty on European sales of Vitrase for use in the posterior region of the eye. Ista has responsibility to file for regulatory approval for Vitrase for vitreous hemorrhage in the EU (there are no plans for development as a spreading agent in...See full deal structure in Biomedtracker
Partners: Otsuka Holdings Co., Ltd. Allergan plc
Pink Sheet Vitrase FDA Reviewers
Pink Sheet Vitrase Clinical Development
Pink Sheet Allergan/ISTA Vitrase review
Pink Sheet ISTA Vitrase User Fee Date Extended
Additional information available to subscribers only: